PDL Biopharma (PDLI) is trading near a 52-week high, and its share price has appreciated more than 30% year to date. This company's revenue comes from licensing its valuable intellectual property to biotech and pharma companies including Roche, Biogen Idec, and Eli Lilly. PDL Biopharma certainly has a unique business model, but it's perhaps known best by investors for its whopping 7.3% dividend yield.
In the following video, health care analyst Max Macaluso and bureau chief Brenton Flynn discuss both the opportunities and risks that face this stock.
